Peptide Tools to Study SARS-CoV-2
About SARS-CoV-2
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), the causative agent of Covid-19, is responsible for the current pandemic. Developing vaccines and therapies that are safe, effective, and rapidly deployable is an urgent global health priority.
JPT's Peptide Tools to Study SARS-CoV2
The global research efforts as well as clinicial trials evaluating vaccines and drugs generates a demand for SARS-CoV-2 related peptide products enabling definition of immune-relevant antigens, identification of B- and T-cell epitopes, development of therapeutic & diagnostic strategies and clinical trial immune monitoring.
In response, JPT has launched a broad development program to provide access to genome spanning SARS-CoV-2 peptide tools for applications such as:
- SARS-CoV-2 clinical trial immune monitoring
- SARS-CoV-2 correlation of cellular and humoral immune responses
- SARS-CoV-2 evaluation of cross reactivities
- SARS-CoV-2 vaccine target identification
- SARS-CoV-2 blood and sero test development
- SARS-CoV-2 T-and B-cell epitope discovery
We have broadened our portfolio of coronavirus related products beyond SARS-CoV-2, including SARS-CoV, MERS-CoV and common cold viruses CoV 229E, OC43, HKU1 and NL63. Have a look!
References with SARS-CoV-2 Peptide Tools
Deconvoluting the T cell response to SARS-CoV-2: specificity versus chance- and cognate cross-reactivity
Lehmann et al, bioRxiv (2020)
Peptide microarray based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development
Holenya et a al, medRxiv (2020)
BNT162b2 Induces SARS-CoV-2-Neutralising Antibodies and T cells in Humans
Sahin et al, medRxiv (2020)
Convalescent Plasma Therapy for B-Cell Depleted Patients With Protracted COVID-19 Disease
Hueso et al, Blood (2020)
Divergent SARS‐CoV‐2‐Specific T and B Cell Responses in Severe but Not Mild COVID‐19 Patients
Oja et al, European Journal of Immunology (2020)
mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
Rauch et al, bioRxiv (2020)
T Cell and Antibody Responses to SARS-CoV-2: Experience From a French Transplantation and Hemodialysis Center During the COVID-19 Pandemic
Candon et al, Am J Transplant (2020)
Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion
Gallais et al, Emerg Infect Dis (2020)
A Glimpse Into the Diverse Cellular Immunity Against SARS-CoV-2
Chang et al, Research Square (2020)
Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and 2 non-human primates
Kalnin et al, bioRxiv (2020)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in Older Adults
Anderson et al, NEJM (2020)
Divergent SARS-CoV-2-specific T and B cell Responses in Severe but Not Mild COVID-19
Oja et al, bioRxiv (2020)
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett et al, New England J of Med (2020)
Presence of SARS-CoV-2 reactive T cells in COVID-19 Patients and Healthy Donors
Braun et al, Nature (2020)
Single-shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado et al, Nature (2020)
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
Corbett et al, bioRxiv (2020)
Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing
Zecha et al, Mol Cell Proteomics (2020)
A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
Payen et al, medRXiv (2020)
SARS-CoV-2-specific T cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative Potential
Neidleman et al, bioRxiv (2020)
Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in vitro by Intracellular Aminopeptidases
Stamatakis et al bioRxiv (2020)
Self-amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
McKay et al, Nature 2020
An mRNA Vaccine Against SARS-CoV-2 — Preliminary Report
Jackson et al, New England J of Med (2020)
SARS‐CoV‐2‐Reactive Interferon‐γ‐producing CD8+ T cells in Patients Hospitalized with Coronavirus Disease 2019
Giminez et al, J Med Vir (2020)
Concurrent Human Antibody and TH1 type T-cell Responses 2 Elicited by a COVID-19 RNA Vaccine
Sahin et al, medRXiv (2020)
Further references
Check our list of products,
click and go.
News Highlights
-
JPT’s SARS CoV-2 Products Deliver Meaningful Results!
(Aug 2020) - NEW! SARS-COV-2 Spike & NCAP Mutations as PepMix™ Peptide Pools
(Aug 2020) - NEW! Study SARS CoV-2 Cross Reactive T-Cells with EMPS-Peptides from Endemic HCoV’s
(Jul 2020) - NEW! SARS COV-2 Mass Spec Reference Kit Released!
(Jul 2020) - NEW! Mission Completed! Purified SARS-CoV-2 PepMixes™ & Peptide Arrays
(Jun 2020)
--> Read more News
Downloads
Quality Assurance
All production is performed according to ISO 9001:2015 standards